Company Release no. 10/2020
To: NASDAQ Copenhagen A/S
Announcement of Request for Delisting of
Following company release no. 9/2020, in which Asahi Kasei Pharma Denmark A/S announced its decision to initiate a compulsory acquisition of the shares held by Veloxis Pharmaceutical A/S' ("Veloxis'") remaining shareholders pursuant to Sections 70-72 of the Danish Companies Act, Veloxis' board of directors has today, upon request from Asahi Kasei Pharma Denmark A/S, decided to request
Provided that Nasdaq Copenhagen accepts the request, the delisting will be completed as soon as possible. The last day of trading is expected to be Monday
For more information, please contact:
CEO CFO
Phone: +1 919-591-3090
Email: IR@Veloxis.com
This announcement has been prepared both in English and Danish. In the event of any discrepancies between the English and Danish version, the English version shall prevail.
About Veloxis
Veloxis is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis operates in the
Attachment
UK - Delisting Request Submitted to Nasdaq
© OMX, source